A recent in vitro study also demonstrated that activating the MET/FAK signalling axis leads to CDK4/6-independent CDK2 activation and could thus become a target to improve the response of cancers to CDK4/6-targeted therapies[45]. This evidence concerns the gene CDK4 and cancer.